The U.S. Food and Drug Administration have approved GlaxoSmith Kline’s version of its H1N1 pandemic vaccine.More than 7 million doses of this vaccine will be delivered to the U.S. in December. The vaccine is the unadjuvanted vaccine for use in adults.